- Home
- BYON vs ELDN Comparison
BYON vs ELDN Comparison
Compare BYON & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYON
- ELDN
- Stock Information
- Founded
- BYON 1997
- ELDN 2004
- Country
- BYON United States
- ELDN United States
- Employees
- BYON N/A
- ELDN N/A
- Industry
- BYON Catalog/Specialty Distribution
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- BYON Consumer Discretionary
- ELDN Health Care
- Exchange
- BYON Nasdaq
- ELDN Nasdaq
- Market Cap
- BYON 173.6M
- ELDN 178.4M
- IPO Year
- BYON N/A
- ELDN N/A
- Fundamental
- Price
- BYON $4.56
- ELDN $2.89
- Analyst Decision
- BYON Hold
- ELDN Strong Buy
- Analyst Count
- BYON 9
- ELDN 1
- Target Price
- BYON $10.67
- ELDN $16.00
- AVG Volume (30 Days)
- BYON 2.5M
- ELDN 160.2K
- Earning Date
- BYON 04-28-2025
- ELDN 05-20-2025
- Dividend Yield
- BYON N/A
- ELDN N/A
- EPS Growth
- BYON N/A
- ELDN N/A
- EPS
- BYON N/A
- ELDN N/A
- Revenue
- BYON $1,244,431,000.00
- ELDN N/A
- Revenue This Year
- BYON N/A
- ELDN N/A
- Revenue Next Year
- BYON $9.09
- ELDN N/A
- P/E Ratio
- BYON N/A
- ELDN N/A
- Revenue Growth
- BYON N/A
- ELDN N/A
- 52 Week Low
- BYON $3.54
- ELDN $2.00
- 52 Week High
- BYON $22.39
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- BYON 54.85
- ELDN 40.93
- Support Level
- BYON $3.75
- ELDN $2.85
- Resistance Level
- BYON $4.08
- ELDN $3.51
- Average True Range (ATR)
- BYON 0.30
- ELDN 0.27
- MACD
- BYON 0.11
- ELDN -0.01
- Stochastic Oscillator
- BYON 84.90
- ELDN 5.63
About BYON Beyond Inc.
Beyond Inc is an online retailer that provides products and services through websites. The company offers a broad range of products, including furniture, décor, area rugs, bedding and bath, home improvement, outdoor, and kitchen and dining items, BMMG (like books, magazines, CDs), electronics, and other items. The home and garden product line accounts for a material part of its total revenue. The company operates through a direct business that makes sales from the company's own inventory, and a partner business that sells merchandise from manufacturers, distributors, and other suppliers through the company's websites. The company generates the majority of its total revenue from partner business in terms of business format, and from the U.S. in terms of market.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.